Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (7133)	9/2/1998 11:38:00 PM
From: aknahow	Respond to of 17367

Bob, good thing your post was opinion! . "Patient enrollment was 226 patients at 6/24/98. Because of the sporadic nature of the disease, future enrollment rates are unpredictable. Patient mortality data is only available to those few individuals at XOMA who monitor patient safety and is otherwise unavailable. Of course, even those employees remain blinded to which patients received drug or placebo." A few at XOMA see total mortality data. Even these remain blinded to which patients got which drug. Anyone is free to believe what they want. I believe the XOMA statement from the FAQ. To believe otherwise is to believe there is no such thing as a double blinded trial.